Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy

Hiroshi Takane, Katsuyuki Kawamoto, Tomohiro Sasaki, Kuniaki Moriki, Kazuyo Moriki, Hiroya Kitano, Shun Higuchi, Kenji Otsubo, Ichiro Ieiri

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Introduction: To explore severe toxicities induced by irinotecan-based chemotherapy and UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes. Case report: A 66-year-old Japanese male diagnosed with left pharyngeal carcinoma (T2N2bM0, stage IVA) was treated with irinotecan (70 mg/m2) on days 1, 8 and 15 in combination with docetaxel (60 mg/m2) on day 1 of a 28-day cycle. After the first cycle, he suffered marked toxicities, including grade 4 diarrhea and febrile grade 4 neutropenia. Plasma concentrations of irinotecan, SN-38 and SN-38G were measured, and extensive accumulation of SN-38 was observed. Genotyping of UGT1A1 and OATP1B1 proteins showed UGT1A1*6/*28 and SLCO1B1*15/*15, respectively, which are known to lead to extremely low glucuronidation and transport activities of substrate drugs. Conclusion: The severe toxicities in this patient are attributable to the extensive accumulation of SN-38, which may result from a synergistic or additive effect of low metabolic (UGT1A1*6/*28) and transport (SLCO1B1*15/*15) capabilities.

Original languageEnglish
Pages (from-to)1165-1169
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume63
Issue number6
DOIs
Publication statusPublished - May 1 2009

Fingerprint

irinotecan
Chemotherapy
Toxicity
Genotype
Drug Therapy
docetaxel
Neutropenia
Diarrhea
Fever

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. / Takane, Hiroshi; Kawamoto, Katsuyuki; Sasaki, Tomohiro; Moriki, Kuniaki; Moriki, Kazuyo; Kitano, Hiroya; Higuchi, Shun; Otsubo, Kenji; Ieiri, Ichiro.

In: Cancer Chemotherapy and Pharmacology, Vol. 63, No. 6, 01.05.2009, p. 1165-1169.

Research output: Contribution to journalArticle

Takane, Hiroshi ; Kawamoto, Katsuyuki ; Sasaki, Tomohiro ; Moriki, Kuniaki ; Moriki, Kazuyo ; Kitano, Hiroya ; Higuchi, Shun ; Otsubo, Kenji ; Ieiri, Ichiro. / Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. In: Cancer Chemotherapy and Pharmacology. 2009 ; Vol. 63, No. 6. pp. 1165-1169.
@article{0cca599974064cf0825f13cc5f049363,
title = "Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy",
abstract = "Introduction: To explore severe toxicities induced by irinotecan-based chemotherapy and UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes. Case report: A 66-year-old Japanese male diagnosed with left pharyngeal carcinoma (T2N2bM0, stage IVA) was treated with irinotecan (70 mg/m2) on days 1, 8 and 15 in combination with docetaxel (60 mg/m2) on day 1 of a 28-day cycle. After the first cycle, he suffered marked toxicities, including grade 4 diarrhea and febrile grade 4 neutropenia. Plasma concentrations of irinotecan, SN-38 and SN-38G were measured, and extensive accumulation of SN-38 was observed. Genotyping of UGT1A1 and OATP1B1 proteins showed UGT1A1*6/*28 and SLCO1B1*15/*15, respectively, which are known to lead to extremely low glucuronidation and transport activities of substrate drugs. Conclusion: The severe toxicities in this patient are attributable to the extensive accumulation of SN-38, which may result from a synergistic or additive effect of low metabolic (UGT1A1*6/*28) and transport (SLCO1B1*15/*15) capabilities.",
author = "Hiroshi Takane and Katsuyuki Kawamoto and Tomohiro Sasaki and Kuniaki Moriki and Kazuyo Moriki and Hiroya Kitano and Shun Higuchi and Kenji Otsubo and Ichiro Ieiri",
year = "2009",
month = "5",
day = "1",
doi = "10.1007/s00280-008-0864-x",
language = "English",
volume = "63",
pages = "1165--1169",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy

AU - Takane, Hiroshi

AU - Kawamoto, Katsuyuki

AU - Sasaki, Tomohiro

AU - Moriki, Kuniaki

AU - Moriki, Kazuyo

AU - Kitano, Hiroya

AU - Higuchi, Shun

AU - Otsubo, Kenji

AU - Ieiri, Ichiro

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Introduction: To explore severe toxicities induced by irinotecan-based chemotherapy and UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes. Case report: A 66-year-old Japanese male diagnosed with left pharyngeal carcinoma (T2N2bM0, stage IVA) was treated with irinotecan (70 mg/m2) on days 1, 8 and 15 in combination with docetaxel (60 mg/m2) on day 1 of a 28-day cycle. After the first cycle, he suffered marked toxicities, including grade 4 diarrhea and febrile grade 4 neutropenia. Plasma concentrations of irinotecan, SN-38 and SN-38G were measured, and extensive accumulation of SN-38 was observed. Genotyping of UGT1A1 and OATP1B1 proteins showed UGT1A1*6/*28 and SLCO1B1*15/*15, respectively, which are known to lead to extremely low glucuronidation and transport activities of substrate drugs. Conclusion: The severe toxicities in this patient are attributable to the extensive accumulation of SN-38, which may result from a synergistic or additive effect of low metabolic (UGT1A1*6/*28) and transport (SLCO1B1*15/*15) capabilities.

AB - Introduction: To explore severe toxicities induced by irinotecan-based chemotherapy and UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes. Case report: A 66-year-old Japanese male diagnosed with left pharyngeal carcinoma (T2N2bM0, stage IVA) was treated with irinotecan (70 mg/m2) on days 1, 8 and 15 in combination with docetaxel (60 mg/m2) on day 1 of a 28-day cycle. After the first cycle, he suffered marked toxicities, including grade 4 diarrhea and febrile grade 4 neutropenia. Plasma concentrations of irinotecan, SN-38 and SN-38G were measured, and extensive accumulation of SN-38 was observed. Genotyping of UGT1A1 and OATP1B1 proteins showed UGT1A1*6/*28 and SLCO1B1*15/*15, respectively, which are known to lead to extremely low glucuronidation and transport activities of substrate drugs. Conclusion: The severe toxicities in this patient are attributable to the extensive accumulation of SN-38, which may result from a synergistic or additive effect of low metabolic (UGT1A1*6/*28) and transport (SLCO1B1*15/*15) capabilities.

UR - http://www.scopus.com/inward/record.url?scp=63949084512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63949084512&partnerID=8YFLogxK

U2 - 10.1007/s00280-008-0864-x

DO - 10.1007/s00280-008-0864-x

M3 - Article

C2 - 18998132

AN - SCOPUS:63949084512

VL - 63

SP - 1165

EP - 1169

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -